Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

9 – Management Of Cardiac And Pulmonary Treatment–related Side Effects

Joseph R. Carver
Published 2011 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
This paper references
10.1200/JCO.2005.13.300
Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
M. Ewer (2005)
10.1200/JCO.2007.25.18_SUPPL.19525
Adherence to anemia treatment guidelines in U.S. community oncology practices
L. Friedman (2007)
10.1007/S11906-007-0058-7
Chemotherapy agents and hypertension: A focus on angiogenesis blockade
Manish Jain (2007)
10.1200/JCO.2005.04.173
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
M. Marty (2005)
10.1097/00001573-200405000-00010
The update on the rationale, use and selection of β-blockers in heart failure
G. Giesler (2004)
10.1016/S0735-1097(03)00759-9
Asymptomatic cardiac disease following mediastinal irradiation.
P. Heidenreich (2003)
10.1378/CHEST.86.5.723
Severe bleomycin-induced pneumonitis. Clinical features and response to corticosteroids.
D. White (1984)
10.7326/0003-4819-133-11-200012050-00012
Prolongation of the QT Interval and Ventricular Tachycardia in Patients Treated with Arsenic Trioxide for Acute Promyelocytic Leukemia
K. Ohnishi (2000)
10.1200/JCO.2007.14.5367
Lenalidomide for the treatment of B-cell malignancies.
A. Chanan-Khan (2008)
10.1093/annonc/mdn168
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate.
M. Telli (2008)
10.1016/S0003-4975(98)00082-4
Surgical management of radiation-induced heart disease.
R. Veeragandham (1998)
10.1016/J.LEUKRES.2007.08.016
Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience.
M. Breccia (2008)
10.1016/J.LUNGCAN.2004.01.010
Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.
T. Takano (2004)
10.1200/JCO.2003.10.009
Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
J. Barbey (2003)
10.1097/00000421-199910000-00009
Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report.
C. Kuropkat (1999)
10.1200/JCO.1995.13.11.2688
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
L. Gianni (1995)
10.1183/09031936.00004808
Hypersensitivity pneumonitis associated with the use of temozolomide
D. Koschel (2009)
10.1200/JCO.1996.14.4.1297
Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease.
A. Hirsch (1996)
10.1016/S0140-6736(94)90008-6
Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer
M. Levine (1994)
10.1200/JCO.2006.08.6595
Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer.
C. Correa (2007)
10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
Reporting results of cancer treatment
A. Miller (1981)
10.1200/JCO.2008.26.15_SUPPL.9569
Tolerance of bevacizumab in an older patient population: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience
S. Richardson (2008)
Preclinical, pharmacologic, and phase I studies of gemcitabine.
A. Storniolo (1997)
10.1259/BJR/66835905
Pulmonary complications following bone marrow transplantation.
T. Wah (2003)
10.1200/JCO.2000.18.8.1725
Cardiovascular morbidity in long-term survivors of metastatic testicular cancer.
M. T. Meinardi (2000)
10.1097/00001813-200603000-00016
Gemcitabine and atrial fibrillation: a rare manifestation of chemotherapy toxicity.
D. Ferrari (2006)
10.1093/annonc/mdn292
Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.
D. Rayson (2008)
10.1007/S11748-006-0070-X
Radiation-induced valvular disease is the logical consequence of irradiation
A. Tamura (2007)
10.1200/JCO.2007.15.5481
Predicting fluorouracil toxicity: can we finally do it?
H. Ezzeldin (2008)
10.1200/JCO.2005.04.120
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
F. Boccardo (2005)
10.1111/j.1540-8159.1999.tb06826.x
Complete Atrioventricular Block after Arsenic Trioxide Treatment in an Acute Promyelocytic Leukemic Patient
C. Huang (1999)
10.1016/S1470-2045(08)70003-2
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.
S. Wu (2008)
10.1161/CIRCULATIONAHA.107.187930
2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina
T. D. Fraker (2007)
10.1200/JCO.2002.20.5.1215
Cardiac dysfunction in the trastuzumab clinical trials experience.
A. Seidman (2002)
10.1016/S0735-1097(00)00748-8
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy.
D. Cardinale (2000)
10.1016/S0009-9260(89)80099-6
Mortality patterns over 34 years of breast cancer patients in a clinical trial of post-operative radiotherapy.
J. M. Jones (1989)
10.1159/000098062
Thrombosis of Internal Carotid Artery after Cisplatin-Based Chemotherapy
J. Pretnar-Oblak (2006)
10.1200/JCO.2003.04.173
Cardiovascular disease as a long-term complication of treatment for testicular cancer.
R. Huddart (2003)
10.1056/NEJMOA053028
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
H. Joensuu (2006)
10.1200/JCO.2005.02.4091
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
E. Tan-chiu (2005)
10.1200/JCO.2005.03.133
Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.
A. Lee (2005)
10.1200/JCO.2005.02.3879
Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
C. Tebbi (2007)
10.4065/83.6.679
Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.
E. Perez (2008)
10.1016/J.ATHORACSUR.2004.04.008
Mitral and tricuspid valve repair in patients with previous mediastinal radiation therapy.
J. Crestanello (2004)
10.5555/URI:PII:0093775482900057
The cardiotoxicity of anticancer agents.
D. V. Von Hoff (1982)
10.1002/CNCR.2820360908
Vincristine‐induced myocardial infarction
Eugen M. Mandel (1975)
10.1016/S0272-5231(03)00126-6
Pulmonary complications of radiation therapy.
R. Abratt (2004)
10.1016/S1040-8428(01)00227-X
Radiation-associated cardiovascular disease.
M. Adams (2003)
10.1200/JCO.2008.18.9043
Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.
B. Monk (2009)
10.1002/j.1552-4604.1993.tb01943.x
Clinical Cardiotoxicity of 5‐Fluorouracil
D. Keefe (1993)
10.1161/01.CIR.94.11.2807
Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.
M. Bristow (1996)
10.1200/JCO.2007.15.6331
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
M. Schmidinger (2008)
10.1002/1097-0142(19870915)60:6<1213::AID-CNCR2820600609>3.0.CO;2-V
Acute arrhythmogenicity of doxorubicin administration
J. Steinberg (1987)
10.7326/0003-4819-125-1-199607010-00008
Anthracycline-Induced Cardiotoxicity
K. Shan (1996)
10.1200/JCO.2008.17.2627
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
M. Hensley (2009)
10.1182/BLOOD.V98.2.266
Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide.
P. Westervelt (2001)
10.1200/JCO.1994.12.10.2078
Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
S. Rivkin (1994)
10.1093/annonc/mdq061
Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer.
T. Shimura (2010)
10.1093/jnci/djp147
Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma.
M. D. De Bruin (2009)
10.1200/JCO.2007.25.18_SUPPL.LBA1008
BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC)
M. Pegram (2007)
10.1002/1097-0142(19851215)56:12<2765::AID-CNCR2820561208>3.0.CO;2-2
Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin
N. Vogelzang (1985)
10.1016/J.THROMRES.2007.06.009
The MASTER registry on venous thromboembolism: description of the study cohort.
G. Agnelli (2008)
10.1200/JCO.2007.14.1283
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.
G. Lyman (2007)
10.1200/JCO.2008.26.15_SUPPL.4103
The safety of long-term bevacizumab use: Results from the BRiTE observational cohort study (OCS)
D. Purdie (2008)
10.1200/JCO.2003.10.066
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
F. Kabbinavar (2003)
10.1002/1097-0142(19930715)72:2<587::AID-CNCR2820720242>3.0.CO;2-V
Severe vascular toxicity associated with cisplatin‐based chemotherapy
F. Içli (1993)
10.1016/j.leukres.2008.03.020
An evaluation of the cardiotoxicity of imatinib mesylate.
A. Ribeiro (2008)
10.1093/OXFORDJOURNALS.ANNONC.A057750
Vascular toxicity and the mechanism underlying Raynaud's phenomenon in patients treated with cisplatin, vinblastine and bleomycin.
S. Hansen (1990)
10.1056/NEJMOA060655
Sorafenib in advanced clear-cell renal-cell carcinoma.
B. Escudier (2007)
10.1200/JCO.1998.16.4.1374
No long-term increase in cardiac-related mortality after breast-conserving surgery and radiation therapy using modern techniques.
A. Nixon (1998)
10.1016/S0301-5629(00)00252-0
Tissue Doppler imaging in detection of myocardial dysfunction in survivors of childhood cancer treated with anthracyclines.
L. Kapusta (2000)
10.1016/J.ATHORACSUR.2007.06.034
Quality of internal thoracic artery grafts after mediastinal irradiation.
B. Gansera (2007)
10.1634/THEONCOLOGIST.6-2-153
Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy.
E. Briasoulis (2001)
10.1182/BLOOD.V98.5.1614
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.
M. Zangari (2001)
10.1634/THEONCOLOGIST.9-1-8
FDA drug approval summaries: oxaliplatin.
A. Ibrahim (2004)
10.1200/JCO.2007.25.18_SUPPL.19521
Early detection of cardiotoxicity during chemotherapy using biomarkers
D. Lenihan (2007)
10.1016/S0140-6736(80)92727-0
MYOCARDIAL INFARCTION FOLLOWING VINBLASTINE TREATMENT
J. Lejonc (1980)
10.1592/PHCO.21.20.1468.34482
Rates of Torsades de Pointes Associated with Ciprofloxacin, Ofloxacin, Levofloxacin, Gatifloxacin, and Moxifloxacin
R. Frothingham (2001)
10.1038/sj.bjc.6602064
Diagnosis and management of drug-associated interstitial lung disease
N. Müller (2004)
10.1212/WNL.0b013e3181c17ea8
Cerebrovascular disease in childhood cancer survivors
Brannon Morris (2009)
10.1200/JCO.2005.05.1037
Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment.
E. Harris (2006)
5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation.
Z. Sasson (1994)
10.1093/JNCI/81.1.59
Myocardial toxic effects during recombinant interleukin-2 therapy.
R. Nora (1989)
10.1056/NEJMOA032691
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
H. Hurwitz (2004)
10.1016/J.CARDFAIL.2005.12.001
Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline.
K. Adams (2006)
10.1345/aph.1C510
Electrocardiographic and Cardiovascular Effects of the 5-Hydroxytryptamine3 Receptor Antagonists
R. Navari (2003)
10.1002/cncr.10182
A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin
I. Dimopoulou (2002)
10.1378/chest.07-0851
Pulmonary complications of novel antineoplastic agents for solid tumors.
B. Vahid (2008)
10.1126/SCIENCE.3798106
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D. Slamon (1987)
10.1001/JAMA.1991.03470120074036
Cardiac toxicity 4 to 20 years after completing anthracycline therapy.
L. Steinherz (1991)
10.1016/S0360-3016(02)02929-2
Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy.
E. Yorke (2002)
10.1136/emj.2008.060574
Coronary spasm induced by capecitabine mimicks ST elevation myocardial infarction
P. Scott (2008)
10.1093/eurheartj/ehn310
Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC).
A. Torbicki (2008)
10.1016/0002-9343(81)90759-2
Ara-C lung: noncardiogenic pulmonary edema complicating cytosine arabinoside therapy of leukemia.
Helen M. Haupt (1981)
10.1093/JNCI/DJI067
Risk of cardiac death after adjuvant radiotherapy for breast cancer.
S. Giordano (2005)
10.1007/s001470050679
Heart transplantation for radiation-associated end-stage heart failure
N. Handa (2000)
10.1089/dis.2008.111714
Cardiovascular late effects and the ongoing care of adult cancer survivors.
J. Carver (2008)
10.1200/JCO.2007.14.9930
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
L. Saltz (2008)
10.1200/JCO.2005.04.1764
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.
N. Robert (2006)
10.1200/JCO.2004.06.033
Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.
O. Hequet (2004)
10.1056/NEJM199103213241205
Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.
S. Lipshultz (1991)
10.1016/S0140-6736(07)61865-0
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
T. F. Chu (2007)
10.1159/000100930
Atrial Fibrillation Induced by Gemcitabine Treatment in a 65-Year-Old Man
Y. Tavil (2007)
10.1016/J.AHJ.2004.12.026
Diastolic dysfunction after mediastinal irradiation.
P. Heidenreich (2005)
10.1016/0300-483X(95)03124-X
Immune-mediated side-effects of cytokines in humans.
T. Vial (1995)
10.1016/0360-3016(94)00429-O
Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems.
S. McDonald (1995)
10.1016/S0167-8140(97)00125-4
Cardiac risk after mediastinal irradiation for Hodgkin's disease.
C. Glanzmann (1998)
10.7326/0003-4819-91-5-710
Risk factors for doxorubicin-induced congestive heart failure.
D. V. Von Hoff (1979)
Capecitabine-related cardiotoxicity: recognition and management.
M. Saif (2008)
10.1183/09031936.98.11051188
Bronchial stenosis and sclerosing mediastinitis: an uncommon complication of external thoracic radiotherapy.
S. T. Dechambre (1998)
10.1093/europace/eup300
Introducing a new entity: chemotherapy-induced arrhythmia.
M. Guglin (2009)
10.1016/J.EUPC.2004.12.012
Doxorubicin-induced second degree and complete atrioventricular block.
S. Kilickap (2005)
10.1056/NEJM200103153441101
USE OF CHEMOTHERAPY PLUS A MONOCLONAL ANTIBODY AGAINST HER 2 FOR METASTATIC BREAST CANCER THAT OVEREXPRESSES HER 2
Ennis (2001)
10.1038/sj.leu.2405062
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
A. Palumbo (2008)
Capecitabine cardiotoxicity--case reports and literature review.
N. Manojlovic (2008)
10.1378/CHEST.99.3.667
Diagnosis of disease caused by Mycobacterium avium complex.
M. Tsukamura (1991)
10.1007/978-0-387-36744-6_14
Cytoprotection for radiation-associated normal tissue injury.
J. Mao (2008)
10.1161/01.CIR.0000039105.49749.6F
Lifetime Risk for Developing Congestive Heart Failure: The Framingham Heart Study
D. Lloyd-Jones (2002)
10.1056/NEJM199008093230604
Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood.
B. O'Driscoll (1990)
10.1016/S0022-5223(99)70250-3
Coronary artery bypass grafting in patients with previous mediastinal radiation therapy.
N. Handa (1999)
10.1023/A:1008380208045
Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicity.
D. Santini (2000)
10.1002/14651858.CD005006.pub4
Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
E. C. van Dalen (2010)
10.1200/JCO.2008.17.1637
Capecitabine-induced coronary vasospasm.
Y. Goldsmith (2008)
10.1159/000079633
Interstitial Lung Disease Induced by Drugs and Radiation
P. Camus (2004)
10.1002/1097-0142(197911)44:5<1588::AID-CNCR2820440508>3.0.CO;2-X
Sudden death during doxorubicin administration
J. Wortman (1979)
10.1183/09031936.01.00225601
Management of malignant pleural effusions.
V. Antony (2001)
10.1182/BLOOD-2007-01-070144
Congestive heart failure is a rare event in patients receiving imatinib therapy.
E. Atallah (2007)
10.1016/S1533-0028(11)70480-7
Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida; January 2007.
J. Bertino (2007)
10.1016/J.LUNGCAN.2007.08.010
The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer.
Lujun Zhao (2008)
Pulmonary complications following bone marrow transplantation.
C. K. Chan (1990)
10.1164/rccm.200710-1501OC
Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.
S. Kudoh (2008)
10.1056/NEJM199108013250501
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
S. Yusuf (1991)
10.1200/JCO.1993.11.7.1208
Cardiac disease following treatment of Hodgkin's disease in children and adolescents.
S. Hancock (1993)
10.1093/JNCI/DJM086
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
F. Scappaticci (2007)
10.1002/cncr.21478
Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone
H. Nakamae (2005)
10.1016/J.CANLET.2005.11.014
BNP as a marker of the heart failure in the treatment of imatinib mesylate.
Y. Park (2006)
10.1056/NEJMOA042934
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
A. Taylor (2004)
10.1182/BLOOD-2001-12-0245
Thromboembolic events during treatment with thalidomide.
E. Urbauer (2002)
10.1001/ARCHINTE.1981.00340060066015
Cardiotoxicity associated with high-dose cyclophosphamide therapy.
J. Gottdiener (1981)
10.1038/bjc.1998.628
Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours.
A. Simpson (1998)
10.1161/CIRCULATIONAHA.108.776831
Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics
M. Chen (2008)
10.1200/JCO.2007.10.9777
American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects.
J. Carver (2007)
10.1016/S0272-5231(03)00123-0
Chemotherapy-induced lung disease.
A. Limper (2004)
10.1136/hrt.2008.149088
Radiation induced heart disease
P. Heidenreich (2009)
10.1200/JCO.2004.10.052
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.
S. Schey (2004)
10.1016/S0959-8049(01)00155-1
Effect of letrozole on the lipid profile in postmenopausal women with breast cancer.
M. Elisaf (2001)
10.1053/CLON.2002.0177
Vascular toxicity associated with cisplatin.
M. King (2003)
10.1097/CAD.0b013e3283165f27
The spectrum of 5-fluorouracil cardiotoxicity
J. Dalzell (2009)
10.1177/030089168206800609
Cardiac Toxicity of 5-Fluorouracil: A Study on 1083 Patients
R. Labianca (1982)
10.1056/NEJMOA065044
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
R. Motzer (2007)
10.1016/S0140-6736(03)14282-1
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
M. Pfeffer (2003)
10.1159/000227621
Review of tests for monitoring doxorubicin-induced cardiomyopathy.
W. Ganz (1996)
10.1016/S0022-3476(78)80443-0
Late-onset pulmonary fibrosis and chest deformity in two children treated with cyclophosphamide.
C. Alvarado (1978)
10.1136/thx.48.1.92
Severe bleomycin lung toxicity: reversal with high dose corticosteroids.
J. Maher (1993)
10.1200/JCO.2007.14.0590
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.
H. Gómez (2008)
10.1001/JAMA.290.21.2831
Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy.
Matthew C. Hull (2003)
10.1097/01.MBC.0000061310.06975.8E
Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study
R. Alikhan (2003)
10.1148/85.1.130
THE EFFECTS OF RADIATION THERAPY ON PULMONARY FUNCTION IN CARCINOMA OF THE LUNG.
L. Brady (1965)
10.1182/BLOOD.V98.2.492
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.
B. Barlogie (2001)
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
M. Cohen (2002)
10.1182/BLOOD-2006-04-015909
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
P. Richardson (2006)
10.1161/01.HYP.0000107251.49515.C2
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
A. Chobanian (2003)
10.1161/01.CIR.0000130926.51766.CC
Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy
D. Cardinale (2004)
10.1056/NEJM199909023411001
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
B. Pitt (1999)
10.1200/JCO.1992.10.9.1386
Hypercholesterolemia after chemotherapy for testis cancer.
D. Raghavan (1992)
10.1093/ANNONC/MDH097
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
M. O'Brien (2004)
10.1378/CHEST.07-0050
Pulmonary toxicity associated with erlotinib.
V. Liu (2007)
10.1158/1078-0432.CCR-08-1124
A Phase I-II Study to Determine the Maximum Tolerated Infusion Rate of Rituximab with Special Emphasis on Monitoring the Effect of Rituximab on Cardiac Function
M. Siano (2008)
10.1200/JCO.2003.02.018
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
H. Burstein (2003)
10.1136/jcp.25.8.668
Pulmonary fibrosis following therapy with Melphalan for multiple myeloma
B. Codling (1972)
10.1182/BLOOD-2002-01-0335
Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.
M. Zangari (2002)
10.3816/CBC.2002.S.004
Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results.
J. O'Shaughnessy (2002)
10.1378/CHEST.99.3.557
Cardiotoxicity of interferon. A review of 44 cases.
M. Sonnenblick (1991)
10.1007/S12094-008-0150-8
Cardiac toxicity: old and new issues in anti-cancer drugs
M. Sereno (2008)
10.1161/CIRCULATIONAHA.106.635144
Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
D. Cardinale (2006)
10.1038/ncponc1244
Prophylactic and therapeutic anticoagulation for thrombosis—major issues in oncology
M. Carrier (2009)
Vindesine-associated angina and ECG changes.
R. J. Yancey (1982)
10.1002/cncr.23460
Heart failure associated with sunitinib malate
A. Khakoo (2008)
10.1634/THEONCOLOGIST.7-1-65
The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?
D. Keefe (2002)
10.1200/JCO.2000.18.17.3078
Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.
B. Hutten (2000)
10.1056/NEJM200106213442516
Deep venous thrombosis and thalidomide therapy for multiple myeloma.
K. Osman (2001)
Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
M. Duvic (2001)
10.1532/IJH97.E0620
Cardiac Toxicity of High-Dose Cyclophosphamide in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
S. Zver (2007)
10.1136/emj.2007.055681
Capecitabine-associated coronary vasospasm: a case report
C. Papadopoulos (2008)
10.1053/J.AJKD.2006.11.039
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.
X. Zhu (2007)
10.1016/J.ATHORACSUR.2004.08.086
Anterior leaflet repair with patch augmentation for mitral regurgitation.
M. Romano (2005)
10.1200/JCO.1997.15.4.1318
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
S. Swain (1997)
10.1200/JCO.2007.13.5467
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
E. Perez (2008)
10.1200/JCO.2007.11.6699
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
A. Seidman (2008)
10.1159/000073351
Side Effects of Ifosfamide
J. Klastersky (2003)
10.1200/JCO.2005.13.755
Cardiac morbidity of adjuvant radiotherapy for breast cancer.
D. Patt (2005)
10.1200/JCO.2006.09.1611
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
T. Suter (2007)
10.1158/1078-0432.CCR-05-2689
Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors
M. Shah (2006)
10.1016/S0140-6736(05)66544-0
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
O. Abe (2005)
10.1002/cncr.22596
Results of a Phase II trial of oral bexarotene (Targretin) combined with interferon alfa‐2b (Intron‐A) for patients with cutaneous T‐cell lymphoma
D. Straus (2007)
10.1200/JCO.2006.07.0805
Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease.
P. Heidenreich (2007)
10.3816/SCT.2006.n.023
Adverse effects of bevacizumab and their management in solid tumors.
Y. Arriaga (2006)
10.1001/JAMA.295.21.2516
Sunitinib in patients with metastatic renal cell carcinoma.
R. Motzer (2006)
10.1200/JCO.2001.19.5.1444
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
G. Batist (2001)
10.2165/00002018-200225040-00004
Safety of Non-Antiarrhythmic Drugs that Prolong the QT Interval or Induce Torsade de Pointes
F. Ponti (2002)
10.1002/CNCR.2820690528
Coronary artery disease mortality in patients treated for hodgkin's disease
J. F. Boivin (1992)
10.1200/JCO.2007.12.1665
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
H. Mouridsen (2007)
10.1001/jama.2008.656
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
S. R. Nalluri (2008)
10.7326/0003-4819-96-2-133
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.
S. Legha (1982)
10.1016/J.JACC.2006.07.052
Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
N. Kalay (2006)
10.1038/ncpcardio1352
A case of cardiogenic shock caused by capecitabine treatment
A. C. To (2008)
10.1158/1078-0432.CCR-05-2095
Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma
R. Piekarz (2006)
10.1007/978-3-642-51190-5
Acute Pulmonary Embolism
S. Konstantinides (2000)
10.1016/J.JTCVS.2006.09.041
Cardiac surgery after mediastinal radiation: extent of exposure influences outcome.
A. S. Chang (2007)
10.1016/J.EJCA.2004.01.011
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.
M. Untch (2004)
10.1378/CHEST.120.2.617
Bleomycin-induced pneumonitis.
S. Sleijfer (2001)
10.1200/jco.20.4.1036
Assessment of coronary heart disease morbidity and mortality after radiation therapy for early breast cancer.
K. Vallis (2002)
10.1200/JCO.1995.13.10.2606
Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors.
M. Roach (1995)
10.1056/NEJMOA025313
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
A. Lee (2003)
10.1200/JCO.2005.04.9551
Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
V. Guarneri (2006)
10.1056/NEJMra0708875
Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma.
B. Cheson (2008)
10.1200/JCO.1998.16.8.2625
Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries.
L. Paszat (1998)
10.1200/JCO.2004.10.002
Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).
A. Kakkar (2004)
10.1200/JCO.1994.12.3.447
Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy.
J. Cuzick (1994)
10.1093/ANNONC/MDJ057
Pulmonary toxicity from novel antineoplastic agents.
I. Dimopoulou (2006)
10.1053/J.SEMINONCOL.2005.03.013
Cardiac toxicity following thoracic radiation.
R. Prosnitz (2005)
10.1016/S0301-5629(01)00470-7
Discriminative ability of conventional echocardiography and tissue Doppler imaging techniques for the detection of subclinical cardiotoxic effects of treatment with anthracyclines.
L. Kapusta (2001)
10.1016/j.hoc.2008.01.010
Long-term cardiac and pulmonary complications of cancer therapy.
J. Yahalom (2008)
10.1001/JAMA.295.2.199
Does this patient have deep vein thrombosis?
P. Wells (2006)
10.1002/1097-0142(197307)32:1<1::AID-CNCR2820320101>3.0.CO;2-X
Phase II evaluation of adriamycin in human neoplasia
R. O'bryan (1973)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar